003520.KO Yungjin Pharm Co Ltd
- Market cap
- KRW 158B
- P/E
- -
- P/B
- 1.98x
- ROE
- -10.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003520.KO undervalued?
Graham numberThe Graham number of Yungjin Pharm Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yungjin Pharm Co Ltd fundamental analysis
No fundamental analysis for Yungjin Pharm Co Ltd yet.
Yungjin Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pha…
Full company profileYungjin Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yungjin Pharm Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 193B | 195B | 186B | 221B | 208B | 196B | 218B | 235B | 252B | 254B | 251B |
| Gross Profit | 71.2B | 68.8B | 61.4B | 79.8B | 73.5B | 57.9B | 64.7B | 72.1B | 80.3B | 77.2B | 74.4B |
| Operating Income | 5.45B | 3.03B | -2.19B | 9.98B | 381M | -13.9B | -7.36B | 3.12B | 8.72B | 4.82B | -6.50B |
| EBITDA | - | 9.85B | 263M | 17.6B | 8.27B | -6.56B | -14.3B | 7.65B | 16.9B | 12.8B | 1.73B |
| Net Income | 4.20B | 1.87B | -6.10B | 5.03B | -133M | -11.6B | -22.0B | -3.88B | 1.23B | -228M | -9.43B |
| EPS | - | 10 | -33 | 28 | -0.73 | -63 | -120 | -21 | 6.74 | -1.24 | -52 |
| Balance Sheet | |||||||||||
| Total Assets | 199B | 204B | 196B | 200B | 188B | 194B | 203B | 227B | 234B | 262B | 227B |
| Total Liabilities | 93.2B | 84.2B | 84.5B | 84.7B | 73.7B | 89.2B | 113B | 137B | 144B | 171B | 141B |
| Shareholders' Equity | 106B | 120B | 112B | 116B | 114B | 105B | 89.9B | 89.6B | 89.8B | 91.5B | 86.2B |
| Cash & Short-term Investments | 1.67B | 4.19B | 1.83B | 652M | 428M | 465M | 682M | 7.21B | 3.44B | 28.4B | 3.59B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.11B | 3.15B | 1.27B | 9.28B | 14.5B | 8.37B | -11.6B | -10.2B | 21.7B | 11.7B | -7.95B |
| Capital Expenditure | 4.69B | 10.6B | 4.71B | 10.4B | 6.30B | 11.3B | 13.2B | 10.2B | 21.6B | 12.0B | 4.60B |
| Free Cash Flow | - | -7.84B | -3.43B | -1.08B | 8.19B | -2.95B | -24.8B | -20.5B | 134M | -234M | -12.6B |
| Ratios | |||||||||||
| ROE | 4.0% | 1.6% | -5.5% | 4.3% | -0.1% | -11.0% | -24.4% | -4.3% | 1.4% | -0.2% | -10.9% |
| ROA | 2.1% | 0.9% | -3.1% | 2.5% | -0.1% | -6.0% | -10.8% | -1.7% | 0.5% | -0.1% | -4.1% |
| Net Profit Margin | 2.2% | 1.0% | -3.3% | 2.3% | -0.1% | -5.9% | -10.1% | -1.6% | 0.5% | -0.1% | -3.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Yungjin Pharm Co Ltd dividends
Yungjin Pharm Co Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 10:5 on Mar 5, 2004.
Who owns Yungjin Pharm Co Ltd
- Insiders 52.45%
- Institutions 0.77%
- Public & others 46.78%
- Shares outstanding 183M
- Free float 86.9M
Yungjin Pharm Co Ltd company profile
- Company name
- Yungjin Pharm Co Ltd
- Ticker
- 003520.KO
- ISIN
- KR7003520004
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 574
- Fiscal year end
- December
- Address
- Jamsil Company Building, Seoul, South Korea, 05510
- Phone
- 82 2 2041 8200
- Website
- yungjin.co.kr
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation.
Yungjin Pharm Co Ltd management
6- Mr. Kisoo LeeChairman of the Board of Directors, President & CEO · born 1966
- Mr. ByeongHo ParkCFO & MD · born 1967
- Mr. UngYeol YangMD & GM of Sales HQ · born 1977
- Mr. Joongyoun ChoMD & Global Headquarters GM · born 1979
- Mr. HongJun ParkManaging Director · born 1974
- Mr. UngGyu LeeVice President · born 1972